irinotecan + mitomycin + oxaliplatin

This is a combination chemotherapy regimen consisting of three cytotoxic agents—irinotecan, mitomycin (as mitomycin C), and oxaliplatin. All three are small molecule chemotherapeutic drugs with distinct but complementary mechanisms of action. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication, leading to cell death. Mitomycin C acts as an alkylating agent that crosslinks DNA, inhibiting DNA synthesis and function. Oxaliplatin is a platinum-based compound that forms both inter- and intra-strand DNA crosslinks, disrupting DNA replication and transcription. This combination has been investigated primarily for the treatment of advanced or metastatic colorectal cancer in patients who have progressed after first-line therapy with fluoropyrimidines/leucovorin[1][2]. The rationale for combining these agents lies in their non-overlapping mechanisms of action and toxicity profiles, which may provide synergistic antitumor effects while maintaining acceptable tolerability[1][2].

Other names

irinotecan plus mitomycin C plus oxaliplatinCPT-11 + MMC + L-OHP